{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:37:33Z","timestamp":1791859053124,"version":"4.3.4"},"reference-count":71,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.japh.2021.03.013","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T22:05:27Z","timestamp":1616796327000},"page":"e1-e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A systematic review and meta-analysis of randomized controlled trials of cardiovascular toxicity of medical cannabinoids"],"prefix":"10.1016","volume":"61","author":[{"given":"Alexandre H.","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leenhapong","family":"Navaravong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitipong","family":"Sirilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5244-8489","authenticated-orcid":false,"given":"Ratthanon","family":"Prasitwarachot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4828-4412","authenticated-orcid":false,"given":"Surakit","family":"Nathisuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Robert L.","family":"Page","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2021.03.013_bib1","unstructured":"United States Department of Health and Human Services. 2013 National Survey on Drug Use and Health: Summary of National Findings. Available at: http:\/\/store.samhsa.gov\/home. Last accessed August 19, 2021."},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/wps.20735","article-title":"Assessing the public health impacts of legalizing recreational cannabis use: the US experience","volume":"19","author":"Hall","year":"2020","journal-title":"World Psychiatry"},{"issue":"23","key":"10.1016\/j.japh.2021.03.013_bib3","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1\u20134","key":"10.1016\/j.japh.2021.03.013_bib4","first-page":"9","article-title":"Analysis of \u201cmarijuana edibles\u201d \u2013 food products containing marijuana or marijuana extracts \u2013 an overview, review and literature survey","volume":"14","author":"Klein","year":"2017","journal-title":"Microgram J"},{"issue":"6","key":"10.1016\/j.japh.2021.03.013_bib5","first-page":"1","article-title":"Deaths: leading causes for 2017","volume":"68","author":"Heron","year":"2019","journal-title":"Natl Vital Stat Rep"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.japh.2021.03.013_bib7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1751-7133.2008.00016.x","article-title":"CB1 cannabinoid receptor inhibition: promising approach for heart failure?","volume":"14","author":"Mukhopadhyay","year":"2008","journal-title":"Congest Heart Fail"},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib8","article-title":"French Association of the Regional Abuse and Dependence Monitoring Centres (CEIP-A) Working Group on Cannabis Complications\u2217. Cannabis use: signal of increasing risk of serious cardiovascular disorders","volume":"3","author":"Jouanjus","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.japh.2021.03.013_bib9","doi-asserted-by":"crossref","first-page":"2091.e3","DOI":"10.1016\/j.ajem.2011.12.033","article-title":"ST-segment elevation myocardial infarction in a 37-year-old man with normal coronaries--it is not always cocaine!","volume":"30","author":"Arora","year":"2012","journal-title":"Am J Emerg Med"},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/AC.69.2.3017293","article-title":"Is recent cannabis use associated with acute coronary syndromes? An illustrative case series","volume":"69","author":"Casier","year":"2014","journal-title":"Acta Cardiol"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jemermed.2013.11.077","article-title":"Cannabis-associated myocardial infarction in a young man with normal coronary arteries","volume":"47","author":"Hodcroft","year":"2014","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.japh.2021.03.013_bib12","year":"2017"},{"key":"10.1016\/j.japh.2021.03.013_bib13","series-title":"Methodological Expectations of Cochrane Intervention Reviews","author":"Higgins","year":"2019"},{"issue":"1","key":"10.1016\/j.japh.2021.03.013_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pedhc.2010.09.006","article-title":"The PRISMA statement: a guideline for systematic reviews and meta-analyses","volume":"25","author":"Swartz","year":"2011","journal-title":"J\u00a0Pediatr Health Care"},{"key":"10.1016\/j.japh.2021.03.013_bib15","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"10.1016\/j.japh.2021.03.013_bib17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","article-title":"Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly","volume":"15","author":"Pacher","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10.1016\/j.japh.2021.03.013_bib19","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/j.1532-2149.2013.00445.x","article-title":"A\u00a0double-blind, randomized, placebo-controlled, parallel group study of THC\/CBD spray in peripheral neuropathic pain treatment","volume":"18","author":"Serpell","year":"2014","journal-title":"Eur J Pain"},{"issue":"12","key":"10.1016\/j.japh.2021.03.013_bib20","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jagp.2015.07.011","article-title":"Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial","volume":"23","author":"van den Elsen","year":"2015","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0885-3924(94)00117-4","article-title":"Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS","volume":"10","author":"Beal","year":"1995","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.japh.2021.03.013_bib22","first-page":"2","article-title":"A\u00a0multicentre, double-blind, randomised, parallel-group, placebo-controlled study of effect of long-term Sativex treatment on cognition and mood of patients with spasticity due to multiple sclerosis","volume":"1","author":"Vachov\u00e1","year":"2013","journal-title":"J\u00a0Mult Scler"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bcp.12811","article-title":"Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability","volume":"81","author":"de Vries","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.japh.2021.03.013_bib24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2125.2010.03743.x","article-title":"Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting","volume":"70","author":"Duran","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"23","key":"10.1016\/j.japh.2021.03.013_bib25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJM197906073002302","article-title":"Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy","volume":"300","author":"Herman","year":"1979","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.japh.2021.03.013_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1681.2012.05674.x","article-title":"Lack of effect of central nervous system-active doses of nabilone on capsaicin-induced pain and hyperalgesia","volume":"39","author":"Kalliom\u00e4ki","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"6","key":"10.1016\/j.japh.2021.03.013_bib27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0885-3924(91)90026-Z","article-title":"Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting","volume":"6","author":"Lane","year":"1991","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"1\u20132","key":"10.1016\/j.japh.2021.03.013_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0304-3959(03)00163-5","article-title":"The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions","volume":"105","author":"Naef","year":"2003","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.japh.2021.03.013_bib29","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jps.20037","article-title":"Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans","volume":"93","author":"Naef","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib30","first-page":"254","article-title":"Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy","volume":"9","author":"Narang","year":"2008","journal-title":"J\u00a0Pain"},{"issue":"8","key":"10.1016\/j.japh.2021.03.013_bib31","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF01728184","article-title":"Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy","volume":"64","author":"Niederle","year":"1986","journal-title":"Klin Wochenschr"},{"issue":"4","key":"10.1016\/j.japh.2021.03.013_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00101-005-0963-6","article-title":"Delta(9)-tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain","volume":"55","author":"Seeling","year":"2006","journal-title":"Anaesthesist"},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib33","first-page":"164","article-title":"Nabilone for the treatment of pain in fibromyalgia","volume":"9","author":"Skrabek","year":"2008","journal-title":"J\u00a0Pain"},{"issue":"5","key":"10.1016\/j.japh.2021.03.013_bib34","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2011.07.036","article-title":"Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome","volume":"141","author":"Wong","year":"2011","journal-title":"Gastroenterology"},{"issue":"3\u20134","key":"10.1016\/j.japh.2021.03.013_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0091-3057(01)00533-0","article-title":"Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac","volume":"69","author":"S\u00f6derpalm","year":"2001","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib36","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.baga.2011.04.002","article-title":"Cannabinoid, CB1 agonists in cervical dystonia: failure in a phase IIa randomized controlled trial","volume":"1","author":"Zadikoff","year":"2011","journal-title":"Basal Ganglia"},{"issue":"7","key":"10.1016\/j.japh.2021.03.013_bib37","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/1097-0142(19810401)47:7<1746::AID-CNCR2820470704>3.0.CO;2-4","article-title":"A\u00a0prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and Cytoxan chemotherapy","volume":"47","author":"Chang","year":"1981","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.japh.2021.03.013_bib38","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1476-5381.2008.00010.x","article-title":"Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans","volume":"156","author":"Beaumont","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"7460","key":"10.1016\/j.japh.2021.03.013_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1136\/bmj.38149.566979.AE","article-title":"Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial","volume":"329","author":"Svendsen","year":"2004","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.japh.2021.03.013_bib40","first-page":"57","article-title":"Bronchial effects of aerosolized delta 9-tetrahydrocannabinol in healthy and asthmatic subjects","volume":"115","author":"Tashkin","year":"1977","journal-title":"Am Rev Respir Dis"},{"issue":"4","key":"10.1016\/j.japh.2021.03.013_bib41","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","article-title":"Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study","volume":"10","author":"Vaney","year":"2004","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib42","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1185\/030079907X167525","article-title":"Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting","volume":"23","author":"Meiri","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"S1","key":"10.1016\/j.japh.2021.03.013_bib43","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1002\/j.1552-4604.1981.tb02576.x","article-title":"Nabilone: an effective antiemetic in patients receiving cancer chemotherapy","volume":"21","author":"Einhorn","year":"1981","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"suppl B","key":"10.1016\/j.japh.2021.03.013_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0305-7372(82)80032-7","article-title":"A\u00a0double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy","volume":"9","author":"Johansson","year":"1982","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"10.1016\/j.japh.2021.03.013_bib45","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"van den Elsen","year":"2015","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.japh.2021.03.013_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/bjc.1983.247","article-title":"Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy","volume":"48","author":"Ahmedzai","year":"1983","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.japh.2021.03.013_bib47","first-page":"946","article-title":"Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial","volume":"79","author":"Chan","year":"1987","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.japh.2021.03.013_bib48","first-page":"24","article-title":"Essal comparatif randomise d'un nouvel anti-emetique: la nabilone, chez des malades cancereuses traitees par le cis-platinum [Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin]","volume":"37","author":"George","year":"1983","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF00256701","article-title":"Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis","volume":"17","author":"Pomeroy","year":"1986","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.japh.2021.03.013_bib50","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"issue":"2\u20133","key":"10.1016\/j.japh.2021.03.013_bib51","first-page":"219","article-title":"Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis","volume":"64","author":"Steele","year":"1980","journal-title":"Cancer Treat Rep"},{"issue":"6","key":"10.1016\/j.japh.2021.03.013_bib52","doi-asserted-by":"crossref","first-page":"819","DOI":"10.7326\/0003-4819-91-6-819","article-title":"Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation","volume":"91","author":"Chang","year":"1979","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00004714-198306000-00004","article-title":"A\u00a0double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa","volume":"3","author":"Gross","year":"1983","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.japh.2021.03.013_bib54","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0277-5379(83)90032-9","article-title":"A\u00a0randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy","volume":"19","author":"Hutcheon","year":"1983","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib55","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2010","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"11","key":"10.1016\/j.japh.2021.03.013_bib56","first-page":"2520","article-title":"Sativex and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis","volume":"262","author":"Leocani","year":"2015","journal-title":"J\u00a0Neurol"},{"issue":"1\u20133","key":"10.1016\/j.japh.2021.03.013_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.japh.2021.03.013_bib58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","article-title":"Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial","volume":"159","author":"Levin","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.japh.2021.03.013_bib59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.ijg.0000212260.04488.60","article-title":"Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study","volume":"15","author":"Tomida","year":"2006","journal-title":"J\u00a0Glaucoma"},{"issue":"1","key":"10.1016\/j.japh.2021.03.013_bib60","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1191\/0269215503cr581oa","article-title":"A\u00a0preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms","volume":"17","author":"Wade","year":"2003","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.japh.2021.03.013_bib61","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ypmed.2017.07.008","article-title":"Cannabis use, attitudes, and legal status in the U.S.: a review","volume":"104","author":"Carliner","year":"2017","journal-title":"Prev Med"},{"issue":"6","key":"10.1016\/j.japh.2021.03.013_bib62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11883-017-0663-0","article-title":"What is the current knowledge about the cardiovascular risk for users of cannabis-based products? A systematic review","volume":"19","author":"Jouanjus","year":"2017","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"10.1016\/j.japh.2021.03.013_bib63","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jacc.2019.11.025","article-title":"Marijuana use in patients with cardiovascular disease: JACC review topic of the week","volume":"75","author":"DeFilippis","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9767","key":"10.1016\/j.japh.2021.03.013_bib64","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(10)62296-9","article-title":"Public health importance of triggers of myocardial infarction: a comparative risk assessment","volume":"377","author":"Nawrot","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.japh.2021.03.013_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJM197407112910203","article-title":"Effect of marihuana and placebo-marihuana smoking on angina pectoris","volume":"291","author":"Aronow","year":"1974","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.japh.2021.03.013_bib66","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijcard.2018.03.113","article-title":"Burden of arrhythmia in recreational marijuana users","volume":"264","author":"Desai","year":"2018","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.japh.2021.03.013_bib67","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-91-6-825","article-title":"Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo","volume":"91","author":"Frytak","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.japh.2021.03.013_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0305-7372(82)80035-2","article-title":"A multi-institutional Phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting","volume":"9","author":"Jones","year":"1982","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.japh.2021.03.013_bib69","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0305-7372(82)80034-0","article-title":"Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy","volume":"9","author":"Wada","year":"1982","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.japh.2021.03.013_bib70","first-page":"64S","article-title":"Nabilone: an effective antiemetic agent in patients receiving cancer chemotherapy","volume":"21","author":"Einhorn","year":"1981","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.japh.2021.03.013_bib71","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00415-012-6634-z","article-title":"Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis","volume":"260","author":"Serpell","year":"2013","journal-title":"J Neurol"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:49:06Z","timestamp":1761544146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319121001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1544319121001114"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2021.03.013","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of randomized controlled trials of cardiovascular toxicity of medical cannabinoids","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2021.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}